24/06/08
Obtention of the market authorization in Germany for Oralair® Grasses
Stallergenes has been granted with the market authorization in Germany for...
28/07/08
Phase III clinical trial for Staloral® 300 in China
Stallergenes launches a phase III clinical trial for Staloral® 300 in...
10/06/08
Phase II/III clinical trial on a tablet for desensitisation to mites
Stallergenes has started a phase II/III clinical trial on a tablet for...
| We comply with the HONcode standard for trustworthy health information: verify here. |
Last update: 28/07/2008
STALLERGENES is a European biopharmaceutical laboratory specialising in the treatment by desensitisation of allergy-related respiratory conditions.
The Group's activities focus on research into allergy, and the development, production and distribution of allergen extracts for the curative treatment of allergic rhinitis and asthma.
Visit the investors website
